Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
November 03, 2023 10:46 ET
|
Travere Therapeutics, Inc.
“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape ..."
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
October 13, 2023 16:30 ET
|
Travere Therapeutics, Inc.
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for...
Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021
November 02, 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data...
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020
October 19, 2020 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of...